How a cancer drug affects immune cells in breast cancer
Immunometabolic pathways enabled by PARP inhibition in breast cancer
['FUNDING_R37'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-10874715
This study is looking at how a type of cancer treatment called PARP inhibitors affects certain immune cells in breast cancer, with the goal of finding better ways to boost the body's immune response and improve treatment outcomes for patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10874715 on ClinicalTrials.gov |
What this research studies
This research investigates how poly (ADP-ribose) polymerase inhibitors (PARPi), a common cancer treatment, influence immune cells known as tumor-associated macrophages (TAMs) in breast cancer. The study aims to understand the dual role of PARPi in promoting harmful TAMs that inhibit T-cell function while simultaneously enhancing the effectiveness of T-cells. By exploring these mechanisms, the research seeks to develop strategies that can improve the immune response against breast cancer, potentially leading to better treatment outcomes for patients. The approach includes analyzing the metabolic changes in TAMs and T-cells to identify ways to enhance T-cell activation and reduce tumor growth.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients undergoing treatment with PARPi who may benefit from enhanced immune responses.
Not a fit: Patients with non-breast cancers or those not receiving PARPi treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies that enhance the immune response against breast cancer, potentially increasing survival rates and quality of life for patients.
How similar studies have performed: While the combination of PARPi and immune checkpoint blockade has shown promise, early phase clinical trials have not yet demonstrated superior outcomes, indicating that this research is exploring a critical and potentially novel area.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUERRIERO, JENNIFER L. — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: GUERRIERO, JENNIFER L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Breast Cancer, Breast Cancer Patient, Breast Cancer Treatment